Condition: Advanced Parkinson Disease · Sponsor: Britannia Pharmaceuticals Ltd.
The primary objective of the study is to assess the effectiveness of LECIGON® treatment on the reduction in OFF time (h/day) from baseline at 12 months as measured by Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part IV (MDS-UPDRS IV).
This description comes directly from the study's public registry record.
Sukhdeep Singh, MSci · +44 07954751548 · Sukhdeep.singh@britannia-pharm.com
Niall Smith, MBA · Niall.smith@britannia-pharm.com
Always discuss trial participation with your own doctor first.
| Complejo Hospitalario Universitario de A Coruña (CHUAC) | A Coruña, A Coruña, Spain | Recruiting |
| Virgen del Rocío University Hospital | Seville, Av. Manuel Siurot, S/n, Spain | Recruiting |
| Hospital Universitario de Toledo | Toledo, Castille-La Mancha, Spain | Recruiting |
| Hospital de Cruces | Barakaldo, Vizcaya, Spain | Recruiting |
| Hospital de Basurto | Bilbao, Vizcaya, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07313176